Employers balk at cost of Ozempic as pressure builds for weight-loss drug coverage
The next flashpoint in employer-sponsored health benefits is here: whether companies should foot the bill for blockbuster weight-loss drugs like Ozempic. As the Wall Street Journal reports, firms are split over the cost-benefit calculus of covering GLP-1 medications, with many limiting access or cutting coverage altogether.
The decision carries weight—